CEBPZ and acute myeloid leukemia: We found that co-occurring myelodysplasia-related mutations did not substantially affect the favorable impact of CBF-AML (CBF-AML with myelodysplasia-associated mutations vs CBF-AML without: CR rates, 93% vs 92%, P = 1.00; DFS, 5-year rates, 57% vs 51%, P = 0.65; OS, 5-year rates, 66% vs 63%, P = 0.65; Supplementary Table 8, Supplementary Fig. 6a, b), or of CEBPAbZIP mutations (CR rates: 76% vs 85%, P = 0.33; DFS, 5-year rates, 38% vs 43%, P = 0.74; OS, 5-year rates: 38% vs 50%, P = 0.49; Supplementary Table 9, Supplementary Fig. 6c, d).